Oxazepam

證據等級: L5

預測適應症: 1 個

Oxazepam: From Anxiety Disorder to Insomnia

One-Sentence Summary

Oxazepam is a benzodiazepine anxiolytic/sedative, classically used to manage anxiety and related conditions. The TxGNN model predicts it may also be effective for Insomnia, with 0 registered clinical trials and 11 supporting publications (including 2 RCTs) currently available, though the drug is not currently marketed in this jurisdiction and key safety documentation is still missing.

Quick Overview

Item	Content
Original Indication	Not available in evidence pack (no license record on file; drug is classically categorized as a benzodiazepine anxiolytic)
Predicted New Indication	Insomnia
TxGNN Prediction Score	99.86%
Evidence Level	L2
US Market Status	✗ Not Marketed
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is flagged as a data gap in the evidence pack. Based on known pharmacology, however, Oxazepam is a benzodiazepine that acts at the benzodiazepine binding site of the GABA-A receptor, enhancing inhibitory GABAergic neurotransmission. This produces sedative, anxiolytic, and hypnotic effects.

This mechanism is the well-established pharmacological basis for benzodiazepine use in insomnia — it is not a novel repurposing hypothesis but rather an extension of a mechanism already widely applied in clinical practice. The predicted link between an anxiolytic/sedative agent and insomnia is therefore mechanistically coherent rather than speculative.

Supporting literature spans four decades (1983–2024) and includes head-to-head hypnotic comparisons (e.g., oxazepam vs. flurazepam in chronic insomnia), use in elderly populations with comorbid insomnia, and use in special clinical contexts such as alcohol withdrawal-related insomnia and perioperative anxiety/sleep disturbance in STEMI patients.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

PMID	Year	Type	Journal	Key Findings
6691478	1984	RCT	Am J Psychiatry	Oxazepam improved polysomnographic sleep measures in chronic insomnia without the daytime sleepiness seen with flurazepam
29749262	2018	RCT	Ann Pharmacother	Compared oxazepam vs. melatonin for anxiety and sleep quality in STEMI patients post-PCI
17317444	2007	Review	Arch Gerontol Geriatr	Effectiveness/safety of hypnotics, including benzodiazepines, for insomnia in patients over 70
36340306	2022	Review	J Clin Exp Hepatol	Insomnia as an early symptom of alcohol withdrawal syndrome; benzodiazepine management in liver disease
23330992	2013	Review	Expert Opin Drug Metab Toxicol	Pharmacokinetics of anxiolytic drugs, including benzodiazepines used for sleep/anxiety
15633073	2005	Review	Psychiatr Prax	Practice patterns for managing behavioral/sleep symptoms in dementia, including benzodiazepine use
23338224	1997	Review	CNS Drugs	Review of anxiolytic pharmacology relevant to panic/anxiety-related sleep disturbance
29844949	2018	Cohort	PeerJ	Factors associated with long-term benzodiazepine/z-drug use (incl. for insomnia) in older adults
39544757	2024	Case report	Am J Transl Res	Adverse sensory event associated with a sedative/hypnotic-class agent (agomelatine); relevant to comparative hypnotic safety
6139491	1983	Case report	JAMA	Withdrawal syndrome after substituting oxazepam (short-acting) for a long-acting benzodiazepine

US Market Information

This drug currently has no license records on file (total_licenses: 0) and market status is listed as not marketed. No authorization/product table is available.

Safety Considerations

Please refer to the package insert for safety information.

(Note: the evidence pack flags a Blocking data gap — TFDA label warnings/contraindications are not yet available — which must be resolved before any safety-related determination can be finalized.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic rationale is strong (well-established benzodiazepine GABA-A pharmacology) and is supported by decades of published literature including two RCTs, but there are no dedicated clinical trials for this specific repurposing use, and the drug is not currently marketed in this jurisdiction with a Blocking data gap on TFDA label warnings/contraindications.

To proceed, the following is needed:

TFDA label warnings/contraindications (DG001, Blocking) — download and parse the official package insert from the TFDA website
Formal mechanism of action documentation from DrugBank (DG002, High) to support the mechanistic-link analysis
Confirmation of local market/licensing status before any regulatory pathway can be pursued
Dedicated safety review given known benzodiazepine risks (dependence, withdrawal, elderly fall risk) once label data is available
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.